HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Abstract
Advanced prostate cancer remains largely incurable, primarily because the very low growth fraction present in these tumors makes them generally resistant to treatment with standard chemotherapeutic agents that target cell division. Effective therapies should therefore induce death of prostate cancer cells, independent of their growth rate. trkA, the high-affinity tyrosine kinase-linked receptor for nerve growth factor, has been implicated in prostatic cancer growth and may represent a molecular target for therapeutic agents. At low mg/kg doses, the trk tyrosine kinase inhibitor CEP-751 (KT6587) inhibits prostatic cancer growth in nine different animal models independent of the tumor growth rate, androgen sensitivity, metastatic ability, or state of tumor differentiation. CEP-751 is selective for cancerous versus normal prostate cells and affects the growth of only a limited number of nonprostate tumors. Importantly, CEP-751 induces cell death of prostate cancer cells in a cell cycle-independent fashion and, therefore, represents a novel therapeutic approach to the management of both hormone-dependent and hormone-independent prostate cancer.
AuthorsC A Dionne, A M Camoratto, J P Jani, E Emerson, N Neff, J L Vaught, C Murakata, D Djakiew, J Lamb, S Bova, D George, J T Isaacs
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 4 Issue 8 Pg. 1887-98 (Aug 1998) ISSN: 1078-0432 [Print] United States
PMID9717816 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • CEP 751
  • Carbazoles
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins
  • Receptors, Nerve Growth Factor
  • Receptor Protein-Tyrosine Kinases
  • Receptor, trkA
Topics
  • Adenocarcinoma (drug therapy, enzymology, pathology)
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Carbazoles (pharmacology)
  • Cell Cycle (drug effects)
  • Cell Death (drug effects)
  • Disease Models, Animal
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Prostatic Neoplasms (drug therapy, enzymology, pathology)
  • Proto-Oncogene Proteins (antagonists & inhibitors, biosynthesis)
  • Rats
  • Rats, Inbred Strains
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, biosynthesis)
  • Receptor, trkA
  • Receptors, Nerve Growth Factor (antagonists & inhibitors, biosynthesis)
  • Transplantation, Heterologous
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: